Skip to main content

Table 2 Accruing clinical trials combining radiosensitizing agents with radiation therapy

From: Radiosensitization in prostate cancer: mechanisms and targets

Trial description

Sponsor

Status

Sunitinib with hormonal ablation in patients with localized prostate cancer

MD Anderson Cancer Center

Ongoing, not recruiting

SU5416 with hormonal ablation in patients with localized prostate cancer

University of Chicago

Unknown

Everolimus with hormonal ablation in patients with high risk localized prostate cancer

University of Michigan

Not yet open

TAK-700 with hormonal ablation in patients with high risk localized prostate cancer

Radiation Therapy Oncology Group

Recruiting

Everolimus with hormonal ablation in patients with high risk locally advanced prostate cancer

Centre Val d’Aurelle – Paul Lamarque

Recruiting

Bevacizumab with hormonal ablation in patients with high risk localized prostate cancer

Benaroya Research Institute

Completed

Everolimus for salvage treatment of biochemical recurrence after prostatectomy

Abramson Cancer Center of the University of Pennsylvania

Recruiting

IL-12 gene therapy

Baylor College of Medicine

Completed

ProstAtakâ„¢ in patients with localized prostate cancer

Advantagene, Inc.

Recruiting

Isoflavones in patients with localized prostate cancer

Barbara Ann Karmanos Cancer Institute

Completed

Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer

University of Alabama

Completed

Selenomethionine in patients with localized prostate cancer

Roswell Park Cancer Center

Withdrawn

R-Flubiprofen in patients with high risk localized prostate cancer

Myrexis Inc.

Unknown

Panobinostat in patients with localized prostate cancer

Novartis Pharmaceuticals

Completed